瘦型非酒精性脂肪性肝病患者的肝脏和心血管损伤及其与内脏肥胖的关系
该回顾性队列研究纳入意大利3个肝脏中心669例经活检证实的非酒精性脂肪性肝病患者,比较瘦型与超重/肥胖患者的肝脏和心血管疾病差异及内脏肥胖的影响。瘦型患者高血压、糖尿病、代谢综合征、非酒精性脂肪性肝炎、纤维化F2及以上和颈动脉斑块比例均显著低于超重/肥胖患者,颈动脉内膜中层厚度更薄。瘦型患者中PNPLA3 rs738409 C>G是NASH和纤维化评分2分及以上的唯一独立相关变量。
要点
- 瘦型非酒精性脂肪性肝病患者中20%存在NASH、纤维化评分2分及以上和颈动脉粥样硬化。
- 瘦型患者NASH、纤维化F2及以上和颈动脉斑块比例显著低于超重/肥胖患者。
- 瘦型患者中PNPLA3 rs738409 C>G是NASH和纤维化评分2分及以上的唯一独立相关变量。
核心结论
- 在瘦型与超重/肥胖非酒精性脂肪性肝病患者的回顾性研究中,发现20%的瘦型患者存在NASH、纤维化评分2分及以上和颈动脉粥样硬化。
- 携带PNPLA3 rs738409 C>G的瘦型患者应监测肝病进展;纳入大量瘦型患者的研究将阐明TM6SF2多态性的可能作用。
研究设计与样本
- 回顾性队列研究,纳入意大利3个肝脏中心669例经活检证实的非酒精性脂肪性肝病患者。
- 瘦型非酒精性脂肪性肝病组143例(女性43例,平均年龄46±13岁),超重/肥胖非酒精性脂肪性肝病组526例(女性149例,平均年龄49±12岁)。
- 超重定义为BMI 25-29.9 kg/m2,肥胖定义为BMI≥30 kg/m2;根据腰围分组评估内脏肥胖。
- 分析PNPLA3 rs738409 C>G、TM6SF2 rs58542926 C>T单核苷酸多态性。
主要发现
- 瘦型患者高血压(P=.001)、糖尿病(P=.0001)和代谢综合征(P=.0001)比例显著低于超重/肥胖患者。
- 瘦型患者NASH比例为17%,超重/肥胖患者为40%(P=.0001);纤维化F2及以上比例为17% vs 42%(P=.0001);颈动脉斑块比例为27% vs 39%(P=.03)。
- 瘦型患者颈动脉内膜中层厚度为0.74±0.1 mm,超重/肥胖患者为0.84±0.3 mm(P=.0001)。
- 瘦型患者携带TM6SF2 rs58542926 C>T比例为4%,超重/肥胖患者为0.3%(P=.001);PNPLA3 rs738409 C>G比例无显著差异。
- 143例瘦型患者中,27例有3级脂肪变,24例小叶炎症评分大于2,10例气球样变评分2,25例纤维化评分2分及以上。
关键数值与推荐
- 瘦型非酒精性脂肪性肝病定义为BMI小于25 kg/m2的非酒精性脂肪性肝病。
- 腰围分组:低腰围男性<94 cm、女性<80 cm;中腰围男性94-102 cm、女性80-88 cm;高腰围男性>102 cm、女性>88 cm。
- 瘦型患者中PNPLA3 rs738409 C>G是NASH和纤维化评分2分及以上的唯一独立相关变量。
- 中腰围瘦型患者糖尿病风险比值比为11(95%CI 1.2-106;P=.03),中腰围超重/肥胖患者比值比为1.3(95%CI 0.4-4.2;P=.6)。
临床怎么用
- 作者认为携带PNPLA3 rs738409 C>G的瘦型患者应监测肝病进展。
- 作者指出纳入大量瘦型患者的研究将阐明TM6SF2多态性的可能作用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Lean nonalcoholic fatty liver disease (NAFLD) is defined as NAFLD that develops in patients with a body mass index (BMI) less than 25 kg/m2. We investigated the differences between lean NAFLD and NAFLD in overweight and obese persons, factors associated with the severity of liver and cardiovascular disease, and the effects of visceral obesity. METHODS: We performed a retrospective cohort study of 669 consecutive patients with biopsy-proven NAFLD seen at 3 liver centers in Italy. We collected anthropometric, clinical, and biochemical data, as well as information on carotid atherosclerosis (artery intima-media thickness and plaque), liver histology (nonalcoholic steatohepatitis [NASH] and fibrosis), insulin resistance, and diabetes. Overweight was defined as a BMI of 25 to 29.9 kg/m2, and obese was defined as a BMI of 30 kg/m2 or greater. Patients were assigned to groups based on waist circumference, a marker of visceral obesity (low: men, <94 cm, women <80 cm; medium: men, 94-102 cm, women 80-88 cm; or high: men >102 cm, women >88 cm). DNA samples were analyzed for the rs738409 C>G (I148M in PNPLA3), the rs58542926 C>T (E167K in TM6SF2), and single-nucleotide polymorphisms. Variables in men and women were analyzed using chi-squared analysis and the Mann-Whitney or Kruskal-Wallis tests. Multiple linear or logistic regression analyses were adjusted for all the variables of clinical relevance or statistically significant at univariate analyses. The primary outcome was the difference in liver and cardiovascular disease between lean NAFLD and NAFLD in overweight and obese persons. Secondary outcomes were effects of visceral obesity, based on waist circumference, on hepatic, vascular, and metabolic features. RESULTS: Significantly lower proportions of patients with lean NAFLD (143 patients; 43 women; mean age, 46 ± 13 y) had hypertension (P = .001), diabetes (P = .0001), and metabolic syndrome (P = .0001) than overweight or obese patients with NAFLD (526 patients; 149 women; mean age, 49 ± 12 y). Significantly lower proportions of patients with lean NAFLD had NASH (17% vs 40% of obese or overweight patients with NAFLD; P = .0001), fibrosis of F2 or higher (17% vs 42%; P = .0001), or carotid plaques (27% vs 39%; P = .03). Patients with lean NAFLD had significantly thinner carotid intima-media (0.74 ± 0.1 mm) than obese or overweight patients with NAFLD (0.84 ± 0.3 mm; P = .0001). There was no significant difference in the proportions of patients with rs738409 C>G in PNPLA3, but a significantly greater proportion of patients with lean NAFLD carried rs58542926 C>T in TM6SF2 (4%) than obese or overweight individuals with NAFLD (0.3%; P = .001). Of the 143 patients with lean NAFLD, 27 had grade 3 steatosis, 24 had a lobular inflammation score greater than 2, 10 had a ballooning score of 2, and 25 had a fibrosis score of 2 or higher. In patients with lean NAFLD, the only variable associated independently with NASH and a fibrosis score of 2 or higher was rs738409 C>G in PNPLA3. Patients with lean NAFLD and a medium waist circumference had a significantly higher risk of diabetes (odds ratio, 11; 95% confidence interval [CI], 1.2-106; P = .03) than overweight or obese patients with a similar waist circumference (odds ratio, 1.3; 95% CI, 0.4-4.2; P = .6). Lean and overweight or obese patients with high waist circumferences had significant increases in risk compared with patients with low and medium circumference and diabetes, hypertension, and fibrosis scores of 2 or higher. CONCLUSIONS: In a retrospective study of patients with lean NAFLD vs obese or overweight persons with NAFLD, we found 20% of patients with lean NAFLD to have NASH, fibrosis scores of 2 or higher, and carotid atherosclerosis. Lean patients with rs738409 C>G in PNPLA3 should be monitored for liver disease progression; studies including large series of patients with lean NAFLD will clarify the possible role of TM6SF2 polymorphisms.
引用
- Fracanzani AL, Petta S, Lombardi R, et al. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. Clin Gastroenterol Hepatol. 2017. PMID: 28554682. doi:10.1016/j.cgh.2017.04.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。